<SEC-DOCUMENT>0001193125-16-610043.txt : 20160601
<SEC-HEADER>0001193125-16-610043.hdr.sgml : 20160601
<ACCEPTANCE-DATETIME>20160601170454
ACCESSION NUMBER:		0001193125-16-610043
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20160601
DATE AS OF CHANGE:		20160601
EFFECTIVENESS DATE:		20160601

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		161689975

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d373416ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No.&nbsp;) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by
a Party other than the Registrant&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Soliciting Material Pursuant to &#167;240.14a-12</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>SANGAMO BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of each class of securities to which the transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate number of securities to which the transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per unit price or other underlying value of the transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposed maximum aggregate value of the transaction:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total fee paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amount Previously Paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form, Schedule or Registration Statement No.:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing Party:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g373416snap4.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SANGAMO BIOSCIENCES ANNOUNCES RETIREMENT OF EDWARD LANPHIER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS PRESIDENT AND CEO; SANDY MACRAE NAMED AS SUCCESSOR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Leadership Transition Underlines Evolution from a Platform Company to a Therapeutic Product Company </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Dr.&nbsp;Macrae Appointed as President and CEO</I> &#150; <I>Mr.&nbsp;Lanphier to Assume Chairmanship of the </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Board of Directors &#150; Current Chairman William Ringo to Remain on the Board </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Company to Host Conference Call and Webcast Today at 8:30 am ET </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Richmond, California</B>, <B>June&nbsp;1, 2016 </B>&#150; Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today
announced the company has appointed Alexander &#145;Sandy&#146; Macrae, M.B., Ch.B, Ph.D., MRCP, as president and chief executive officer to succeed current president and CEO, Edward Lanphier. Mr.&nbsp;Lanphier is retiring from the day-to-day
leadership of Sangamo. He will continue as a member of the board of directors and, as previously disclosed, will assume the chairmanship of the board immediately following the 2016 annual meeting of stockholders which will be held on June&nbsp;14,
2016. Mr.&nbsp;William Ringo, Sangamo&#146;s current chairman since 2010, will remain on the board as chairman of the Nominating and Governance Committee and member of the Compensation Committee. Dr.&nbsp;Macrae has assumed the CEO role effective
today. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Macrae, a physician scientist with deep experience in clinical development and global business strategy, most recently served as global
medical officer of Takeda Pharmaceuticals where he established and led its global medical office. In the 15 years prior, Dr.&nbsp;Macrae held roles of increasing responsibility at Smith Kline Beecham and Glaxo SmithKline (GSK), where his last role
was as Senior Vice President, Emerging Markets Research and Development (R&amp;D). During his time at GSK he led therapeutic product development activities in neurology, cardiovascular and metabolic diseases and served in senior business development
roles. Dr.&nbsp;Macrae earned his B.Sc. in pharmacology and his medical degree from Glasgow University, and a Ph.D. in molecular genomics at King&#146;s College, Cambridge, under the supervision of Nobel Prize-winner Sydney Brenner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Sangamo has successfully evolved from a platform company into a clinical-stage therapeutic product development organization based on our powerful zinc
finger DNA-binding protein (ZFP) genome editing technology,&#148; said Mr.&nbsp;Lanphier. &#147;Sandy is the right person to take Sangamo forward into this next stage of our evolution as a company. He has a track record of building and growing
organizations and his outstanding leadership and communication skills will be critical to the continued development of the company&#146;s therapeutic pipeline and current and future partnering activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am extremely honored to be given the opportunity to take the helm at Sangamo &#150; a company that established the field of genome editing and leads
the sector as an innovator in the development of novel human therapeutics based on this exciting technology. I look forward to building on the visionary work of Edward, one of the true pioneers and leaders in the gene and cell therapy
industry,&#148; said Dr.&nbsp;Macrae. &#147;With multiple ZFP Therapeutics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in clinical development, we have an exciting path forward as we focus on the clinical development and
commercialization of one-time potentially curative therapies.&#148; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g373416snap4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;My commitment to Sangamo is unwavering, as is my passion for the company&#146;s people, technology and
mission to bring one-time long lasting treatments to patients. I look forward to my continued involvement both in helping Sandy transition into his new role and as the chairman of the board of directors,&#148; concluded Mr.&nbsp;Lanphier. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Over a year ago, as it became clear that Sangamo was moving from a platform company to a therapeutic product development company, the board discussed a
leadership succession plan as the company entered this next phase of growth,&#148; said Mr.&nbsp;Ringo, the current chairman of the board. &#147;The board feels strongly that Sandy has the right skill set to advance the company&#146;s goals and we
look forward to benefiting from his experience and leadership.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Edward has been a driving force behind the company and its vision and I look
forward to continuing to collaborate with him as the new chairman of the board,&#148; continued Mr.&nbsp;Ringo. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Alexander &#147;Sandy&#148;
Macrae, M.B., Ch.B., Ph.D., MRCP </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Macrae has nearly 20 years of experience in the pharmaceutical industry across a wide range of therapeutic
areas in Europe, the United States and emerging markets. Since 2012, he has served as global medical officer of Takeda Pharmaceuticals, where he established and led the global medical office, which encompasses medical affairs, regulatory affairs,
pharmacovigilance, outcomes research and epidemiology, quantitative sciences and knowledge and informatics. From 2001 to 2012, Dr.&nbsp;Macrae held roles of increasing responsibility at Glaxo SmithKline (GSK), where his last role was as senior vice
president, emerging markets research and development (R&amp;D). In that position, he provided expertise and resources to create a first-of-its-kind group to expand GSK&#146;s global reach by providing R&amp;D strategies, clinical development and
regulatory resources to enter emerging markets and Asia-Pacific. Earlier in his career at GSK, he was vice president, business development. In that position, he was responsible for scientific assessment and business development project leadership
for the neurology, psychiatry, cardiovascular and metabolic therapeutic areas. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Macrae received his B.Sc. in pharmacology with first-class honors and his M.B., Ch.B. with honors from Glasgow University. He is a member of the
Royal College of Physicians. Dr.&nbsp;Macrae earned his Ph.D. in molecular genomics at King&#146;s College, Cambridge, under the supervision of Nobel Prize-winner Sydney Brenner. He was a Wellcome Trust Advance Training Fellow at Hammersmith
Hospital in London and a Howard Hughes Research Associate at Duke University Medical Center in Durham, N.C., where he conducted post-doctoral research in molecular pharmacology under the guidance of Nobel Prize winner Robert Lefkowitz. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sangamo will host a conference call
today, June&nbsp;1 at 8:30 a.m. ET, which also will be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under &#147;Events and Presentations&#148;
<U>http://investor.sangamo.com/events.cfm</U>. A replay of the webcast will be available for two weeks after the call. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conference call dial-in
numbers are (877)&nbsp;377-7553 for domestic callers and (678)&nbsp;894-3968 for international callers. The conference ID number for the call is 24796846. A conference call replay will be available for one week following the conference call, from
approximately 11:30 a.m. ET on June&nbsp;1, 2016, to 11:30 a.m. ET on June&nbsp;8, 2016. The conference call replay numbers for domestic and international callers are (855)&nbsp;859-2056 and (404)&nbsp;537-3406, respectively; ID number: 24796846.
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g373416snap4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Sangamo </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for monogenic and infectious
diseases by deploying its novel DNA-binding protein technology platform in therapeutic genome editing and gene regulation. The Company&#146;s proprietary In Vivo Protein Replacement Platform&#153; (IVPRP) approach is focused on monogenic diseases,
including hemophilia and lysosomal storage disorders. Based on its proprietary IVPRP approach, Sangamo is initiating Phase 1/2 clinical trials for hemophilia B and MPS I, the first <I>in vivo</I> genome editing applications cleared by the FDA. In
addition, Sangamo has a Phase 2 clinical program to evaluate the safety and efficacy of novel ZFP Therapeutics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the treatment of HIV/AIDS (SB-728). The Company has also formed a strategic
collaboration with Biogen Inc. for hemoglobinopathies, such as sickle cell disease and beta-thalassemia, and with Shire International GmbH to develop therapeutics for Huntington&#146;s disease. It has established strategic partnerships with
companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company&#146;s website at <U>www.sangamo.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ZFP Therapeutic<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is a registered trademark of Sangamo BioSciences, Inc. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains forward-looking statements regarding Sangamo&#146;s current expectations. These forward looking statements include, without
limitation, references to leadership transition, the research and development of ZFNs and ZFP TFs, clinical trials and therapeutic applications of Sangamo&#146;s ZFP technology platform. These statements are not guarantees of future performance and
are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the early stage of ZFP Therapeutic development, the lengthy and uncertain
regulatory approval process, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics, and the ability to establish
strategic partnerships. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo and its partners will be able to develop commercially viable gene-based therapeutics. Actual results may differ from
those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo&#146;s operations and business environments. These risks and uncertainties are described more fully in Sangamo&#146;s Annual Reports on Form 10-K and
Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required
under applicable law. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Sangamo
BioSciences, Inc. </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elizabeth Wolffe, Ph.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(510)
970-6000, x271 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Important Additional Information Filed with the SEC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release may be deemed to be solicitation material in respect of the solicitation of proxies from stockholders in connection with Sangamo&#146;s
2016 annual meeting of stockholders (the &#147;Annual Meeting&#148;). Sangamo and its directors and certain executive officers are deemed participants in the solicitation of proxies from stockholders in connection with the Annual Meeting. On
April&nbsp;25, 2016, Sangamo filed a definitive proxy statement relating to the Annual Meeting, and Sangamo has distributed the Notice of Internet Availability of Proxy Materials to its security holders. The definitive proxy statement will contain
important information regarding the participants in the solicitation and proposals submitted to the stockholders for approval at the Annual Meeting, including the proposal to elect directors of Sangamo. </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g373416snap4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholders of Sangamo are advised to read the definitive proxy statement prior to voting at the Annual
Meeting. Stockholders of Sangamo may obtain, free of charge once they become available, copies of the definitive proxy statement and other documents filed by Sangamo with the SEC at the internet website maintained by the SEC at www.sec.gov. These
documents may also be obtained free of charge by calling investor relations at Sangamo at (510)&nbsp;970-6000. </I></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g373416snap4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g373416snap4.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M'&>&7/ZXH ZVR\7>'=1U"6PM-:LY;R)S&\ F <,#@C!Y/- &S0 4 % !0 4
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M5O\ :XR#[T 1_ OXBS65^G@[6)6-O*2+)I.L3_\ //Z'MZ'CO0!]%4 +0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MK>FQZ>UO&)O/BG,MNR<Y_>,B888.01TP<GG#;BHMWV_K^O\ AKJSNDNO]?\
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MCTK7K:/3KV;Y$D#9AE)[<_=)]\CWH ]2NM/MVT2?3HX8X[9H&A$:*%55*D8
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M\*>7X<FP-^9US[?(: .L^ %Q)-\,41^D-W*B?3@_S)H ]2H * "@ H * "@
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M7:.Q90Q_4F@#N?C\K6^E>#;5^'CM7##T(6,4 7O"UC"G[,.MO=(-DQFE3/\
M>#*%/_?2T ._9H5,^(6V?/\ N1N]OFXH S?")CU_]I;4;LJ)(H9[AAGD84%
M?Y4 3?M)30KJN@6<:(KI#+(P4 <,P _]!- ';^)5'AC]G4VCG;(-.B@Q_M/@
M'^9H ^9;K1[JRT?3]3F7$%^9!#[[" 3^9_2@"WJOAR?2?#FBZK<$@ZJ)7C0C
MHBD '\<G\,4 ?3FKS'2_V?'8G:PT5$_%D"_^S4 <S^S9;E/#>M7&,>9=*F?7
M:F?_ &:@#GOVDM4CFU[1=+1@6MH'F<#MO( _] H ]4^#VCOHWPQTF*52LMPK
M7+ _[9R/TQ0!W= !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 5=2ODTS2KN_E&8[:%YF&<9"
M@G^E3.3C%M*Y<(\\E'N<U9^,Y9] NM4>'2YMCQPPQZ?J?VG=,[!1&Y\M=ARR
M_P![J3CCG24;64=;NWEZW]+LSB[ZO9*[[_=_P=RY!XK,>F7\VH:=+'?6$YMY
M;6SW7)=]H==A"@D%6!R0H'.< 9K.<E&"DNM_PO?\ON\]"DGS6?E]S_X.EO(T
M- U<:YX<L-7,/V<7<"S>66W;,C.,X&:TJI4V[O8E:MI=VON=C)M_%&J7=O;Z
MI;Z 9=$N'4)*DY:Y,;' E\@)C;R#]_=MYQGY:2332EHW^'KV\][/RNQRTYK:
MVO\ .V]OTVN;2:YI$FJ2:6FJV;:A&,O:B=3*HQG)3.1P<]*E---K9 ]&DQ++
M7M'U&66*QU:RNI(D$DBPW".44C(8@'@$=Z;T3;V0=>7J9]QXOTHZ<M[I5Y::
MHGVJ"V?[-<JX0R2*F25STW9QWQ32;DEWO^";#2TGV5R_KVJ?V'X?U#5?)\[[
M';O-Y>[;OV@G&<''3TJ).UK=TOO=BX1YI6,RUU_6$U+3K;5-'M88M0W+%):7
MK3E&"%_G5HDPN 1D$\X&.<UIRVDX]5K]S2_5&2E>"FMG;\35M];TF[OY["VU
M2SFO+<$S01SJTD>#@[E!R/QJ+IQYNA3T=GN5=8\1V>F:#<ZG#+!=F.S>\AB2
M8#ST4 Y4C/'*\@$<BJL^91\TO2[L5"/,[%UM6T^*^M["6^MHKZX7?%;-*HD<
M=RJYR1P>@[46NVET,XRO!2?4>NH63QP2)>0,EPVR%A(")&P3A?4X4\#T/I26
MNWK\NY7?R_X;\]"M!XBT.YDNHX-9L)7LP3<*ERC&$ X.\ _+C'>A:KF6W^>P
M/1\KW&/XGT".VAN6UO3Q!.YBBD-T@61QP54YP3GL*F4K*Z[77GZ!M=OIOY$F
M@:K_ &YH%AJGD^1]KA67R]V[;D9QG S^5:3CRNP/1M=FU]SL:-2 4 % !0 4
M % !0!FZ_%=S^'-3BL"1>/;2+"1P=Y4XQ^- 'R=\*- NM6^(]C&FH1V%S92B
M=A(2)'"GYD4=SC.0>V: /HCXQ:A!I_PMUGSP";A%@C4]V9AC\N3^% 'EWA O
MX8_9S\0:JY*2:G(\</N#B//_ *%^5 &Y^S?H_D:#J^L.F&N9U@0G^Z@R?U;]
M* .?_:1U,3>(-'TM6S]GMVE8>[M@?HM 'H?CC'A[X!2V;_*Z:=#:X]R%4_UH
M E^!=I]E^%>GL1@SRRRG_OLC^2T >'^*X3XD^/=S9K\PGU..#U^52JG] : -
M[]HR]$_C33+!.3;V8) ]68_T H V?B?+_P (?\%/#OA13MN;M4,P]E^=_P#Q
M]EH T?@3;_V!\--<\13C"2.\@)[I$A_KNH P_P!G2QDO?$^N:U,-QCA";C_>
M=LG_ -!H Q_&<A\=?'^'3(SOMXKF.S&.?D0Y?]=] '>?M&:E]F\):7I49P;J
MZWE1_=1?\6% '-?$OPDZVWPW\*VRXF:(P'V8F/>?S)- %?X_6L-MJ_A;0K-=
MJ6UGLC0#H"P4?^@T =S\<+M=%^$MOI:MAKB2&W ']U!N/_H(H F^$1M/"/P:
MCU?4Y5M[>1I+N1CZ9VK^)"C ]Z /(=(L+WXQ_%B>[EC9+)Y1+<'M% O"KGU(
M 'U)- 'UC'&D,211J$C0!54= !T% #Z "@ H * "@ H * "@ H * "@ H *
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M (#1+I'PPU;6& !>>63)_NQH/ZYH X3X"VYU7XI7.I3_ #20VTL^3_?9@O\
M[,: .D^-^=0^)OA#2NJDID?[\H'_ ++0!Z_J?AF+4O&&B:Y*RXTN.8(A'5G"
M@'\ #0!XCXYV^(?VD-)TX'=';26\3#V'[QOYF@"/]H[7%N?$&EZ)&^19PF:0
M>C.>/T7]: .4TZ?QG\48=+\+62 :;I\:1[8U*0QA1C?(>Y_R!0!]+^!_!6G>
M!M 33;$;Y6^:XN",-,_J?;T':@#I: %H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#F];U+
M6%\3:9H^E3V5O]IMYIY);FV>;&PH  %D3'WSW/2B-Y.7DE^+8Y644^[M^%R'
M2/$=S->OI^HW=I]J@U!K/S(+=PER1#YN%&X^6P'7)8?*1U(PXVE%279_@[7]
M/U]!23BVGY?CT?\ 6S3&ZKXZTZ+1=5GTR?S+NUM9IX1-;R)%-Y8Y*,0!(H.,
ME">O6I33L^FGW-K7_@[%QC>:B_Z?;U\M]^Q>C\9:&UE=74EXT4=H$,YE@DC*
MASA6 902I/1AD'!YXJGI]]OGVMWU1E!MI7[7^74CB\<:!+<" 7-PDOFK$ZR6
M4Z&)F("B3<@\O=N&"V >V:$N:UOZ\O7RW^]#;M_7X^GGMOV99_X2O1AJPTW[
M4WGF;R-WD2>5YN,^7YNW9O\ ]G=GMBE'WMOZMO;O\NS[#E[N_P#5]K]NF_==
MQMKXNT2]U)-/M[J1IWEDA4FWD5&D3.] Y7:6&TG&<X&>E$?>5UVO\M/\PE[K
ML_0H7/C2S?6-)T_3I/.-W>&!W>WD",HC<L8Y" KD,H!VEL9HI^_+RLW_ )?+
MS].XY>[%M[JWYI6]=]-]/)F[J^I1:-HU[J<ZL\5I"TK*O5@HS@>YJ6VME=[+
MU>B'&*D[-V,JSE\5QW5G->QZ?/:7!Q-!;(R26F1D'S&<B4 _*<*I.<@<8K2R
M3Y7KY_\  \_Z\LT^:/,ON_K[R"P\4SW7B^;3G@1=.<R0VLX!R\L6WS03G'\1
M &/^6;5,/>BV_5>E[?G9^C14_=:2]'ZM<R^5OQ.FED\J%Y-I;8I; [XJ)RY(
MN78J,>:21Q_A[Q;>W=QI8U22P,6K63WT'V8,IMU3:2CDL=_#CY@%Y4\>FLDH
M<T9/6*3;Z6_K;NO0A-RM)+1MJW7K_EKV96B\<:C=:+K^H06,<:V=W%#;F5&(
M2%UC/G2@'. KER!@@#!Q@FILTH\VC;:?E9_GTWM?K8K[34==+KS>NWD[:=UY
MZ$EIXKU6\L88+>73Y[JZU$V=KJ$43FUF01F1I F_) "LF Y!8=>U.S?*EIHV
M[]EHOOT^3OKI=72YGNE;[WI;Y;_AHPU'QO=Z=X#N-4-K%+K,)G@\E ?+:2$L
M'?KD)A"W7/09R14MWY7'K9^B;2?XNR\[="X0]YQET?WWU7X:OM9]CM+>0RVT
M4C  N@8X]Q5S7+)I&-.3E!2?4DJ2PH * "@ H * "@!* "@#AO&_PJ\.^-@T
M\\1LM2QQ>0 !C_O#HW\_>@#@_C-HGB4^ ]"TJ/3FU&#3E5KF^@Z[E4H/W?)
M(.2: .R^">JQZE\+M-12/,LF>WD'H0V1^A% 'C(OX;S]I1+I)5>(ZN%5P<@X
M.T?RH [W]I-"?#&BOV6[8?FA_P * .[\,W&/@]I]Q$>4T@,,>HB_^M0!Y/\
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M-*,;22?VFUZ6NE^*^YVWU(OS0NM/=YOS=ON7WG=U(S@YOB]X5M_&W_"+22W
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M5R.1^!XJYI1=EM^G0F-[6ENM'ZK1EZI&% !0 4 % !0 4 )0 4 % !0 4 %
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M_3T7EIJ]0WNWY?)+I^=_-_(OZ-HQTG1S9O<FXGE9Y9YRFWS)')9F"]AD\#/
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M45X!_P"@7-_X%2?XT '_  HKP#_T"YO_  *D_P : #_A17@'_H%S?^!4G^-
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$0!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
